Regen Biopharma Preferred Stock, Series A (RGBPP)

[Natureboy1]

On August 17, 2021 the United States Patent and Trademark Office ( “USPTO”) issued Patent Number 11,090,332 B2 to Regen Biopharma, Inc. for “Antigen Specific MRNA Cellular Cancer Vaccines”.
Disclosed in the patented invention are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGEN BIOPHARMA, INC.

Dated: August 25,2021 By: /s/ David Koos
David Koos
Chief Executive Officer